Effects of chitosan-titanium dioxide-Glucantime nanoassemblies on Leishmania major: An in vitro and in vivo study

Articles in Press

Document Type : Original Article

Authors

1 Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Pharmaceutics, School of Pharmacy and Novel Drug Delivery Systems Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran

3 Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

5 Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

10.22038/ijbms.2025.88456.19102

Abstract

Objective(s): Leishmaniasis, a neglected tropical disease, remains a public health concern. Meglumine antimonate (Glucantime®) is associated with high toxicity, prolonged treatment duration, and the emergence of drug resistance. This study aims to investigate a therapeutic strategy using chitosan-titanium dioxide-Glucantime (C-TiO₂-G) nanoassemblies comprising the natural polymer chitosan for drug loading, TiO₂ nanoparticles for enhanced cellular uptake, and Glucantime as the antileishmanial agent. 
Materials and Methods: Cytotoxicity was evaluated in the J774.A1 macrophage cell line to determine the IC50 values, and anti-leishmanial activity against Leishmania major (L. major) amastigotes was assessed using the Giemsa staining method. Lesion size, parasite burden, and tissue histopathology were monitored in BALB/c mice. Additionally, gene expression analysis was conducted to assess the expression of M1 and M2 macrophage polarization markers (CCR7 and CD163). 
Results: The nanoassemblies treatment exhibited reduced cytotoxicity with a significantly higher IC50 (1202.5 ± 3.5 μg/ml at 72 hr) in comparison with Glucantime (999.5 ± 3.5 μg/mL at 72 hr; P<0.05). Treatment with nanoassemblies (100 mg/kg) significantly reduced lesion size and parasite burden in the spleen and liver of the L. major-infected BALB/c mice compared with those in the negative control group (P<0.05). Histopathological analysis revealed less tissue damage in the liver, skin, spleen, and lymph nodes. Treatment with nanoassemblies led to immune modulation, as indicated by significant upregulation of CCR7 expression (P<0.0001) and downregulation of CD163 expression (P<0.05).
Conclusion: The findings highlight the potential of chitosan-titanium dioxide-Glucantime nanoassemblies as a promising therapeutic strategy against leishmaniasis.

Keywords

Main Subjects

References

1. Grifferty G, Shirley H, McGloin J, Kahn J, Orriols A, Wamai R. Vulnerabilities to and the socioeconomic and psychosocial impacts of the leishmaniases: A review. Res Rep Trop Med 2021; 12:135-151.
2. Sajjadi SE, Eskandarian A-A, Shokoohinia Y, Yousefi H-A, Mansourian M, Asgarian-Nasab H, et al. Antileishmanial activity of prenylated coumarins isolated from ferulago angulata and prangos asperula. Res Pharm Sci 2016; 11:324-331.
3. Akyol E, Polat ZA. Investigation of in vitro and in vivo therapeutic activity of tarantula cubensis extract (theranekron®) on Leishmania major. J Vector Borne Dis 2024; 61:594-600.
4.Organization WH. Global leishmaniasis surveillance update, 2023. Geneva: World Health Organization; 2024.
5. Zhang H, Yan R, Liu Y, Yu M, He Z, Xiao J, et al. Progress in antileishmanial drugs: Mechanisms, challenges, and prospects. PLoS Negl Trop Dis 2025; 19:e0012735.
6. Walker J, Gongora R, Vasquez JJ, Drummelsmith J, Burchmore R, Roy G, et al. Discovery of factors linked to antimony resistance in Leishmania panamensis through differential proteome analysis. Mol Biochem Parasitol 2012; 183:166-176.
7. Registre C, Soares R, Rubio KTS, Santos ODH, Carneiro SP. A systematic review of drug-carrying nanosystems used in the treatment of leishmaniasis. ACS Infect Dis 2023; 9:423-449.
8. Litwin I, Mucha S, Pilarczyk E, Wysocki R, Maciaszczyk-Dziubinska E. Complex mechanisms of antimony genotoxicity in budding yeast involves replication and topoisomerase i-associated DNA lesions, telomere dysfunction and inhibition of DNA repair. Int J Mol Sci 2021; 22:4510-4539.
9. Rahnama V, Motazedian MH, Mohammadi-Samani S, Asgari Q, Ghasemiyeh P, Khazaei M. Artemether-loaded nanostructured lipid carriers: Preparation, characterization, and evaluation of: In vitro: Effect on: Leishmania major. Res Pharm Sci 2021; 16:623-633.
10. Pereira MB, Sydor BG, Memare KG, Verzignassi Silveira TG, Alessi Aristides SM, Dalmarco EM, et al. In vivo efficacy of meglumine antimoniate-loaded nanoparticles for cutaneous leishmaniasis: A systematic review. Nanomedicine (Lond) 2021; 16:1505-1518.
11. Jamshaid H, Din Fu, Khan GM. Nanotechnology based solutions for anti-leishmanial impediments: A detailed insight. J Nanobiotechnology 2021; 19:106-156.
12. Godoy-Gallardo M, Eckhard U, Delgado LM, de Roo Puente YJD, Hoyos-Nogués M, Gil FJ, et al. Antibacterial approaches in tissue engineering using metal ions and nanoparticles: From mechanisms to applications. Bioact Mater 2021; 6:4470-4490.
13. Irshad MA, Nawaz R, Rehman MZu, Adrees M, Rizwan M, Ali S, et al. Synthesis, characterization and advanced sustainable applications of titanium dioxide nanoparticles: A review. Ecotoxicol Environ Saf 2021; 212:111978.
14. Ikram M, Javed B, Hassan SWU, Satti SH, Sarwer A, Raja NI, et al. Therapeutic potential of biogenic titanium dioxide nanoparticles: A review on mechanistic approaches. Nanomedicine (Lond) 2021; 16:1429-1446.
15. Ardean C, Davidescu CM, Nemeş NS, Negrea A, Ciopec M, Duteanu N, et al. Factors influencing the antibacterial activity of chitosan and chitosan modified by functionalization. Int J Mol Sci 2021; 22:7449-7476.
16. Wu K, Yan Z, Wu Z, Li J, Zhong W, Ding L, et al. Recent advances in the preparation, antibacterial mechanisms, and applications of chitosan. J Funct Biomater 2024; 15:318-338.
17. Katebi A, Riazi-Rad F, Varshochian R, Ajdary S. Plga nanoparticle-delivered Leishmania antigen and tlr agonists as a therapeutic vaccine against cutaneous leishmaniasis in BALB/c mice. Int Immunopharmacol 2024; 138:112538.
18. Oryan A, Mehrabani D, Owji SM, Hatam GR, Asgari Q. Morphologic changes due to cutaneous leishmaniosis in balb/c mice experimentally infected with Leishmania major. J APPL ANIM RES 2008; 34:87-92.
19. Al-Ibrahimi LAA-Q, Al-Shabani H, Alwan MS. Study of some histopathological changes occurring in white laboratory mice infected with cutaneous leishmaniasis in al–diwaniyah province, iraq. Al-Qadisiyah J Pure Sci 2021; 26:130-137.
20. Salguero FJ, Garcia-Jimenez WL, Lima I, Seifert K. Histopathological and immunohistochemical characterisation of hepatic granulomas in Leishmania donovani-infected BALB/c mice: A time-course study. Parasit Vectors 2018; 11:73-81.
21. Tomiotto-Pellissier F, Bortoleti BTdS, Assolini JP, Gonçalves MD, Carloto ACM, Miranda-Sapla MM, et al. Macrophage polarization in leishmaniasis: Broadening horizons. Front Immunol 2018; 9: 2529-2540.
22. Costa-da-Silva AC, Nascimento DO, Ferreira JRM, Guimarães-Pinto K, Freire-de-Lima L, Morrot A, et al. Immune responses in leishmaniasis: An overview. Trop Med Infect Dis 2022; 7:54-69.
23. Liu J, Geng X, Hou J, Wu G. New insights into m1/m2 macrophages: Key modulators in cancer progression. Cancer Cell Int 2021; 21:389-395.
24. Alcaraz-Serna A, Bustos-Morán E, Fernández-Delgado I, Calzada-Fraile D, Torralba D, Marina-Zárate E, et al. Immune synapse instructs epigenomic and transcriptomic functional reprogramming in dendritic cells. Sci Adv 2021; 7:eabb9965.
25. Cutolo M, Campitiello R, Gotelli E, Soldano S. The role of M1/M2 macrophage polarization in rheumatoid arthritis synovitis. Front Immunol 2022; 13:867260. 
26. Das S, Mukherjee S, Ali N. Super enhancer-mediated transcription of mir146a-5p drives m2 polarization during Leishmania donovani infection. PLoS Pathog 2021; 17:e1009343.
27. Varshosaz J, Arbabi B, Pestehchian N, Saberi S, Delavari M. Chitosan-titanium dioxide-glucantime nanoassemblies effects on promastigote and amastigote of Leishmania major. Int J Biol Macromol 2018; 107:212-221.
28. Dumetz F, Cuypers B, Imamura H, Zander D, D’Haenens E, Maes I, et al. Molecular preadaptation to antimony resistance in Leishmania donovani on the indian subcontinent. mSphere 2018; 3:e00548-17. 
29. Sharma L, Dhiman M, Singh A, Sharma MM. Green approach: A forwarding step for curing leishmaniasis—a neglected tropical disease. Frontiers in Molecular Biosciences 2021; 8:655584.
30. Saleh AH. Potential role of titanium dioxide (tio2) nanoparticles against the toxicity of Leishmania tropica in adult Albino male rats. J Glob Pharma Technol 2019; 11:453-457.
31. Zahir AA, Chauhan IS, Bagavan A, Kamaraj C, Elango G, Shankar J, et al. Green synthesis of silver and titanium dioxide nanoparticles using euphorbia prostrata extract shows shift from apoptosis to G0/G1 arrest followed by necrotic cell death in Leishmania donovani. Antimicrob Agents Chemother 2015; 59:4782-4799.
32. Chaubey P, Mishra B, Mudavath SL, Patel RR, Chaurasia S, Sundar S, et al. Mannose-conjugated curcumin-chitosan nanoparticles: Efficacy and toxicity assessments against Leishmania donovani. Int J Biol Macromol 2018; 111:109-120.
33. Albalawi AE, Khalaf AK, Alyousif MS, Alanazi AD, Baharvand P, Shakibaie M, et al. Fe3o4(@)piroctone olamine magnetic nanoparticles: Synthesize and therapeutic potential in cutaneous leishmaniasis. Biomed Pharmacother 2021; 139:111566.
34. Molaie S, Ghaffarifar F, Dalimi A, Zuhair MH, Sharifi Z. Evaluation of synergistic therapeutic effect of shark cartilage extract with artemisinin and glucantime on visceral leishmaniasis in BALB/c mice. Iran J Basic Med Sci 2019; 22:146-153.
35. Dehghani F, Farhadian N, Mashayekhi Goyonlo V, Ahmadi O. A novel topical formulation of the leishmaniasis drug glucantime as a nanostructured lipid carrier-based hydrogel. Am J Trop Med Hyg 2023; 109:301-314.
36. Rodrigues MR, Santos LMO, Miyazaki CK, Martins VT, Ludolf FR, Kursancew AC, et al. Immunodiagnosis of human and canine visceral leishmaniasis using recombinant Leishmania infantum prohibitin protein and a synthetic peptide containing its conformational b-cell epitope. J Immunol Methods 2019; 474:112641.
37. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005; 366:1561-1577.
38. Silva LC, Castro RS, Figueiredo MM, Michalick MS, Tafuri WL, Tafuri WL. Canine visceral leishmaniasis as a systemic fibrotic disease. Int J Exp Pathol 2013; 94:133-143.
39. Muñoz-Durango N, Gómez A, García-Valencia N, Roldán M, Ochoa M, Bautista-Erazo DE, et al. A mouse model of ulcerative cutaneous leishmaniasis by leishmania (viannia) panamensis to investigate infection, pathogenesis, immunity, and therapeutics. Front Microbiol 2022; 13:907631.
40. Ward JM, Rehg JE, Morse HC, 3rd. Differentiation of rodent immune and hematopoietic system reactive lesions from neoplasias. Toxicol Pathol 2012; 40:425-434.
41. Jang E, Cho S, Pyo S, Nam JW, Youn J. An inflammatory loop between spleen-derived myeloid cells and Cd4(+) T cells leads to accumulation of long-lived plasma cells that exacerbates lupus autoimmunity. Front Immunol 2021; 12:631472.
42. Groenen AG, Lipscomb M, Bossardi Ramos R, Sadhu S, Bazioti V, Fredman G, et al. Resolvin d1 suppresses macrophage senescence and splenic fibrosis in aged mice. Prostaglandins Leukot Essent Fatty Acids 2024; 202:102634.
43. Aguilar Torrentera F, Lambot MA, Laman JD, Van Meurs M, Kiss R, Noël JC, et al. Parasitic load and histopathology of cutaneous lesions, lymph node, spleen, and liver from balb/c and c57bl/6 mice infected with Leishmania mexicana. Am J Trop Med Hyg 2002; 66:273-279.
44. Floro ESM, Roque GAS, de Oliveira Coser L, Jorge GP, de Oliveira ALR, Rocha FJS, et al. Macrophage polarisation during Leishmania (viannia) braziliensis infection in mice. Parasite Immunol 2025; 47:e70001.
45. Emerson LE, Gioseffi A, Barker H, Sheppe A, Morrill JK, Edelmann MJ, et al. Leishmania infection-derived extracellular vesicles drive transcription of genes involved in M2 polarization. Front Cell Infect Microbiol 2022; 12:934611.
46. Katebi A, Varshochian R, Riazi-Rad F, Ganjalikhani-Hakemi M, Ajdary S. Combinatorial delivery of antigen and TLR agonists via plga nanoparticles modulates Leishmania major-infected-macrophages activation. Biomed Pharmacother 2021; 137:111276.
Iranian Journal of Basic Medical Sciences

Articles in Press, Accepted Manuscript
Available Online from 27 August 2025

Files

Share

How to cite

Statistics